Anders Vadsholt, Orphazyme CEO

Or­p­hazyme ad­mits this may be the end, as it asks court to over­see re­struc­tur­ing

Just a cou­ple weeks af­ter Or­p­hazyme ad­mit­ted Eu­ro­pean reg­u­la­tors were un­like­ly to ap­prove its FDA-re­ject­ed drug, the biotech in­di­cat­ed it may shut down en­tire­ly. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.